Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
Results from a phase 3 study of 1L atezolizumab vs single-agent chemotherapy in ...
Prof Siow-Ming Lee - University College London, London, UK
Results from a phase 3 study of 1L atezolizumab vs single-agent chemotherapy in pts with NSCLC ( Prof Siow-Ming Lee - University College London, London, UK )
12 Sep 2022
RADICALS-HD trial: androgen deprivation therapy with post-operative radiotherapy...
Prof Chris Parker - Institute of Cancer Research, Sutton, UK
RADICALS-HD trial: androgen deprivation therapy with post-operative radiotherapy to treat prostate cancer ( Prof Chris Parker - Institute of Cancer Research, Sutton, UK )
12 Sep 2022
ESMO 2022: Latest in PARP inhibitors for metastatic prostate cancer
Dr Neal Shore, Dr Pasquale Rescigno, Prof Noel Clarke and Dr Friederike Schlürma...
ESMO 2022: Latest in PARP inhibitors for metastatic prostate cancer ( Dr Neal Shore, Dr Pasquale Rescigno, Prof Noel Clarke and Dr Friederike Schlürmann )
11 Sep 2022
Adjuvant nivolumab plus ipilimumab vs placebo for localised renal cell carcinoma...
Dr Robert Motzer, Memorial Sloan Kettering Cancer Center, New York, USA
Adjuvant nivolumab plus ipilimumab vs placebo for localised renal cell carcinoma at high risk of relapse after nephrectomy ( Dr Robert Motzer, Memorial Sloan Kettering Cancer Center, New York, USA )
11 Sep 2022
A new era of early cancer detection with blood test may change cancer screening ...
Dr Deb Schrag, Memorial Sloan Kettering Cancer Center, New York, USA
A new era of early cancer detection with blood test may change cancer screening paradigms ( Dr Deb Schrag, Memorial Sloan Kettering Cancer Center, New York, USA )
11 Sep 2022
Pembrolizumab with chemoradiation therapy vs placebo plus CRT for locally advanc...
Prof Jean-Pascal Machiels - Cliniques Universitaires Sain-Luc, Brussels, Belgium
Pembrolizumab with chemoradiation therapy vs placebo plus CRT for locally advanced head and neck squamous cell carcinoma ( Prof Jean-Pascal Machiels - Cliniques Universitaires Sain-Luc, Brussels, Belgium )
11 Sep 2022
Pembrolizumab plus chemo shows prolonged OS and PFS improvement vs chemo for squ...
Dr Silvia Novello - University of Turin, Turin, Italy
Pembrolizumab plus chemo shows prolonged OS and PFS improvement vs chemo for squamous NSCLC ( Dr Silvia Novello - University of Turin, Turin, Italy )
11 Sep 2022
Nivolumab ipilimumab combo does not improve DFS for RCC after nephrectomy
Dr Robert Motzer - Memorial Sloan Kettering Cancer Center, New York, USA
Nivolumab ipilimumab combo does not improve DFS for RCC after nephrectomy ( Dr Robert Motzer - Memorial Sloan Kettering Cancer Center, New York, USA )
11 Sep 2022
Tislelizumab OS benefit vs sorafenib as first line treatment for unresectable he...
Prof Richard S Finn - UCLA Health Santa Monica Cancer Care, Santa Monica, USA
Tislelizumab OS benefit vs sorafenib as first line treatment for unresectable hepatocellular carcinoma ( Prof Richard S Finn - UCLA Health Santa Monica Cancer Care, Santa Monica, USA )
11 Sep 2022
Pembro + CRT in HNSCC fails to deliver statistically significant event-free surv...
Prof Jean-Pascal Machiels - Cliniques Universitaires Sain-Luc, Brussels, Belgium
Pembro + CRT in HNSCC fails to deliver statistically significant event-free survival improvement ( Prof Jean-Pascal Machiels - Cliniques Universitaires Sain-Luc, Brussels, Belgium )
11 Sep 2022
Lenvatinib remains standard of care for first-line therapy in advanced hepatocel...
Prof Richard S Finn - UCLA Health Santa Monica Cancer Care, Santa Monica, USA
Lenvatinib remains standard of care for first-line therapy in advanced hepatocellular carcinoma ( Prof Richard S Finn - UCLA Health Santa Monica Cancer Care, Santa Monica, USA )
11 Sep 2022
New era of early cancer detection blood tests on the horizon
Dr Deborah Schrag - Memorial Sloan Kettering Cancer Center, New York City, USA
New era of early cancer detection blood tests on the horizon ( Dr Deborah Schrag - Memorial Sloan Kettering Cancer Center, New York City, USA )
11 Sep 2022